Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue: −1.90%
EPS: −47.2%
Free cash flow: −30.3%
Total debt: −0.43%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

41.73 0.12 −0.29%

Follow TEVA

Alert me

Market cap: $48.7B
P/E: 92.6×
Fwd P/E: 30.7×
Dividend yield: —
F-score: 8/9
Altman Z: 0.79
Beneish M: −2.35
Dividend safety: 52/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. (TEVA) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by segment, and margins
United States	9,186	53.23%
Europe	5,040	29.20%
International Markets	2,162	12.53%
Other Activities	870	5.04%
Gross margin		51.79%
Operating margin		12.50%
Pre-tax margin		7.09%

Revenue by product or service $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Sale of goods	14,605 84.63%	14,050 84.93%	12,979 81.91%	12,766 85.53%	13,829 87.10%	14,354 86.16%	14,510 85.92%	15,881 86.92%	19,256 88.12%	19,989 91.26%	—
Distribution	1,551 8.99%	1,576 9.53%	1,615 10.19%	1,519 10.18%	1,390 8.75%	1,495 8.97%	1,514 8.97%	1,373 7.51%	1,384 6.33%	963 4.40%	—
Licensing arrangements	678 3.93%	173 1.05%	681 4.30%	212 1.42%	160 1.01%	129 0.77%	147 0.87%	165 0.90%	327 1.50%	314 1.43%	—
Other	423 2.45%	745 4.50%	570 3.60%	428 2.87%	500 3.15%	680 4.08%	716 4.24%	852 4.66%	886 4.05%	637 2.91%	—
Generics	—	—	—	—	—	—	—	—	—	—	10,540 53.63%
Branded	—	—	—	—	—	—	—	—	—	—	8,338 42.43%
Other Products	—	—	—	—	—	—	—	—	—	—	774 3.94%
Revenue	17,258	16,544	15,846	14,925	15,878	16,659	16,887	18,271	21,853	21,903	19,652

Revenue by segment $m

Line	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
United States	9,186 53.23%	8,034 48.56%	7,731 48.79%	7,003 46.92%	—	—	—	—	—	—	—
Europe	5,040 29.20%	5,103 30.85%	4,837 30.53%	4,525 30.32%	4,886 30.77%	4,757 28.56%	4,795 28.39%	5,186 28.38%	5,466 25.01%	4,969 22.69%	—
International Markets	2,162 12.53%	2,463 14.89%	2,351 14.84%	2,352 15.76%	2,032 12.80%	2,154 12.93%	2,246 13.30%	2,422 13.26%	2,863 13.10%	4,015 18.33%	—
Other Activities	870 5.04%	944 5.71%	926 5.84%	1,045 7.00%	1,151 7.25%	1,302 7.82%	1,304 7.72%	1,366 7.48%	1,383 6.33%	1,141 5.21%	—
North America	—	—	—	—	7,809 49.18%	8,447 50.71%	8,542 50.58%	9,297 50.88%	12,141 55.56%	11,778 53.77%	—
Generics	—	—	—	—	—	—	—	—	—	—	10,540 53.63%
Specialty	—	—	—	—	—	—	—	—	—	—	8,338 42.43%
Other, not broken out	—	—	—	—	—	—	—	—	—	—	774 3.94%
Revenue	17,258	16,544	15,846	14,925	15,878	16,659	16,887	18,271	21,853	21,903	19,652

Operating income by segment $m, and margin

	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Corporate Segment	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
United States	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Europe	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
International Markets	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Other Segments	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Segments and Other Activities	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
North America	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Specialty	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Generics	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Corporate and other	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Operating income	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

Operating figures as reported in each quarter’s results release or filing

Figure	Quarter	Latest	A year before	Change
AJOVY exit market share in the United States	Q3 FY2026	32.8%	32.0%	—
Share of total U.S. generic prescriptions	Q3 FY2026	5.80%	6.70%	—
Total prescriptions	Q3 FY2026	227.0M	261.0M	−13.03%

	Q3 FY2026	Q2 FY2026	Q1 FY2026	Q4 FY2025	Q3 FY2025	Q2 FY2025	Q1 FY2025	Q4 FY2024	Q3 FY2024	Q2 FY2024	Q1 FY2024	Q4 FY2023
AJOVY exit market share in the United States	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Share of total U.S. generic prescriptions	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Total prescriptions	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡	‡

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.